Cargando…

Changes in Lymphangiogenesis and Vascular Endothelial Growth Factor Expression by Neo‐Adjuvant Hormonal Therapy in Prostate Cancer Patients

BACKGROUND: The anti‐cancer mechanism of neo‐adjuvant hormonal therapy (NHT) is not well understood. Lymphangiogenesis plays an important role in cancer progression and is regulated by a complex mechanism that includes vascular endothelial growth factor (VEGF) signaling. However, there is little inf...

Descripción completa

Detalles Bibliográficos
Autores principales: Asai, Akihiro, Miyata, Yasuyoshi, Matsuo, Tomohiro, Shida, Yohei, Hakariya, Tomoaki, Ohba, Kojiro, Sakai, Hideki
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2016
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5260425/
https://www.ncbi.nlm.nih.gov/pubmed/27527525
http://dx.doi.org/10.1002/pros.23244
_version_ 1782499404852232192
author Asai, Akihiro
Miyata, Yasuyoshi
Matsuo, Tomohiro
Shida, Yohei
Hakariya, Tomoaki
Ohba, Kojiro
Sakai, Hideki
author_facet Asai, Akihiro
Miyata, Yasuyoshi
Matsuo, Tomohiro
Shida, Yohei
Hakariya, Tomoaki
Ohba, Kojiro
Sakai, Hideki
author_sort Asai, Akihiro
collection PubMed
description BACKGROUND: The anti‐cancer mechanism of neo‐adjuvant hormonal therapy (NHT) is not well understood. Lymphangiogenesis plays an important role in cancer progression and is regulated by a complex mechanism that includes vascular endothelial growth factor (VEGF) signaling. However, there is little information regarding relationship between lymphangiogenesis and androgen deprivation. The aim of this study was to clarify changes in lymphangiogenesis and VEGF expression induced by androgen deprivation in prostate cancer in vivo and in vitro. METHODS: Patients who had undergone a radical prostatectomy were enrolled in the study (NHT, n = 60 and non‐NHT, n = 64). Lymph vessels were identified by D2‐40 immunoreactivity and lymph vessel density and lymph vessel area (LVD and LVA, respectively) were measured from micrographs. The expression of VEGF‐A, ‐B, ‐C, and ‐D was evaluated by immunohistochemistry. The prognostic value of LVD and LVA for biochemical recurrence was also investigated. RESULTS: Mean LVD ± SD was higher in the NHT than in the non‐NHT group (11.3 ± 3.0 vs. 7.1 ± 3.4 per high power field; P < 0.001). LVA was larger in the NHT than in the non‐NHT group (512.8 ± 174.9 vs. 202.7 ± 72.8 µm(2); P < 0.001). VEGF‐A expression was lower whereas VEGF‐C and ‐D levels were higher in the NHT than in the non‐NHT group. VEGF‐B expression in specimens with NHT was lower than that in biopsy specimens at diagnosis. These results were confirmed by in vitro studies used androgen‐sensitive prostate cancer cell line. LVA was found to be an independent predictor of biochemical recurrence in patients who received NHT. CONCLUSIONS: Our results demonstrate that NHT stimulates lymphangiogenesis via upregulation of VEGF‐C and ‐D, which may increase LVA and affect the outcome of prostate cancer patients. This findings were supported by in vitro data of prostate cancer cell. Prostate 77:255–262, 2017. © 2016 The Authors. The Prostate Published by Wiley Periodicals, Inc.
format Online
Article
Text
id pubmed-5260425
institution National Center for Biotechnology Information
language English
publishDate 2016
publisher John Wiley and Sons Inc.
record_format MEDLINE/PubMed
spelling pubmed-52604252017-02-07 Changes in Lymphangiogenesis and Vascular Endothelial Growth Factor Expression by Neo‐Adjuvant Hormonal Therapy in Prostate Cancer Patients Asai, Akihiro Miyata, Yasuyoshi Matsuo, Tomohiro Shida, Yohei Hakariya, Tomoaki Ohba, Kojiro Sakai, Hideki Prostate Original Articles BACKGROUND: The anti‐cancer mechanism of neo‐adjuvant hormonal therapy (NHT) is not well understood. Lymphangiogenesis plays an important role in cancer progression and is regulated by a complex mechanism that includes vascular endothelial growth factor (VEGF) signaling. However, there is little information regarding relationship between lymphangiogenesis and androgen deprivation. The aim of this study was to clarify changes in lymphangiogenesis and VEGF expression induced by androgen deprivation in prostate cancer in vivo and in vitro. METHODS: Patients who had undergone a radical prostatectomy were enrolled in the study (NHT, n = 60 and non‐NHT, n = 64). Lymph vessels were identified by D2‐40 immunoreactivity and lymph vessel density and lymph vessel area (LVD and LVA, respectively) were measured from micrographs. The expression of VEGF‐A, ‐B, ‐C, and ‐D was evaluated by immunohistochemistry. The prognostic value of LVD and LVA for biochemical recurrence was also investigated. RESULTS: Mean LVD ± SD was higher in the NHT than in the non‐NHT group (11.3 ± 3.0 vs. 7.1 ± 3.4 per high power field; P < 0.001). LVA was larger in the NHT than in the non‐NHT group (512.8 ± 174.9 vs. 202.7 ± 72.8 µm(2); P < 0.001). VEGF‐A expression was lower whereas VEGF‐C and ‐D levels were higher in the NHT than in the non‐NHT group. VEGF‐B expression in specimens with NHT was lower than that in biopsy specimens at diagnosis. These results were confirmed by in vitro studies used androgen‐sensitive prostate cancer cell line. LVA was found to be an independent predictor of biochemical recurrence in patients who received NHT. CONCLUSIONS: Our results demonstrate that NHT stimulates lymphangiogenesis via upregulation of VEGF‐C and ‐D, which may increase LVA and affect the outcome of prostate cancer patients. This findings were supported by in vitro data of prostate cancer cell. Prostate 77:255–262, 2017. © 2016 The Authors. The Prostate Published by Wiley Periodicals, Inc. John Wiley and Sons Inc. 2016-08-16 2017-02-15 /pmc/articles/PMC5260425/ /pubmed/27527525 http://dx.doi.org/10.1002/pros.23244 Text en © 2016 The Authors. The Prostate Published by Wiley Periodicals, Inc. This is an open access article under the terms of the Creative Commons Attribution‐NonCommercial‐NoDerivs (http://creativecommons.org/licenses/by-nc-nd/4.0/) License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non‐commercial and no modifications or adaptations are made.
spellingShingle Original Articles
Asai, Akihiro
Miyata, Yasuyoshi
Matsuo, Tomohiro
Shida, Yohei
Hakariya, Tomoaki
Ohba, Kojiro
Sakai, Hideki
Changes in Lymphangiogenesis and Vascular Endothelial Growth Factor Expression by Neo‐Adjuvant Hormonal Therapy in Prostate Cancer Patients
title Changes in Lymphangiogenesis and Vascular Endothelial Growth Factor Expression by Neo‐Adjuvant Hormonal Therapy in Prostate Cancer Patients
title_full Changes in Lymphangiogenesis and Vascular Endothelial Growth Factor Expression by Neo‐Adjuvant Hormonal Therapy in Prostate Cancer Patients
title_fullStr Changes in Lymphangiogenesis and Vascular Endothelial Growth Factor Expression by Neo‐Adjuvant Hormonal Therapy in Prostate Cancer Patients
title_full_unstemmed Changes in Lymphangiogenesis and Vascular Endothelial Growth Factor Expression by Neo‐Adjuvant Hormonal Therapy in Prostate Cancer Patients
title_short Changes in Lymphangiogenesis and Vascular Endothelial Growth Factor Expression by Neo‐Adjuvant Hormonal Therapy in Prostate Cancer Patients
title_sort changes in lymphangiogenesis and vascular endothelial growth factor expression by neo‐adjuvant hormonal therapy in prostate cancer patients
topic Original Articles
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5260425/
https://www.ncbi.nlm.nih.gov/pubmed/27527525
http://dx.doi.org/10.1002/pros.23244
work_keys_str_mv AT asaiakihiro changesinlymphangiogenesisandvascularendothelialgrowthfactorexpressionbyneoadjuvanthormonaltherapyinprostatecancerpatients
AT miyatayasuyoshi changesinlymphangiogenesisandvascularendothelialgrowthfactorexpressionbyneoadjuvanthormonaltherapyinprostatecancerpatients
AT matsuotomohiro changesinlymphangiogenesisandvascularendothelialgrowthfactorexpressionbyneoadjuvanthormonaltherapyinprostatecancerpatients
AT shidayohei changesinlymphangiogenesisandvascularendothelialgrowthfactorexpressionbyneoadjuvanthormonaltherapyinprostatecancerpatients
AT hakariyatomoaki changesinlymphangiogenesisandvascularendothelialgrowthfactorexpressionbyneoadjuvanthormonaltherapyinprostatecancerpatients
AT ohbakojiro changesinlymphangiogenesisandvascularendothelialgrowthfactorexpressionbyneoadjuvanthormonaltherapyinprostatecancerpatients
AT sakaihideki changesinlymphangiogenesisandvascularendothelialgrowthfactorexpressionbyneoadjuvanthormonaltherapyinprostatecancerpatients